NOVN and NVS Related Headlines
Go Back- Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
- Novartis completes seventh US facility plan with North Carolina site
- Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
- NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"
- Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally
- Novartis wins FDA approval for oral chronic urticaria treatment
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
- M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
- Monte Rosa surges premarket on Novartis collaboration deal
- Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
- Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial
- Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
- Avidity Biosciences stock soars on Novartis takeover approach report
- FDA approves NOVN's Leqvio for first-line cholesterol treatment
- Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
- Novartis fails to block MSN from selling generic heart drug Entresto
NOVN and NVS Related Press Releases
Go Back- Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
- Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
- NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"
- Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
- Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
- Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
- Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
NOVN and NVS Related SEC Filings
Go Back- Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor
- Form 6-K NOVARTIS AG For: Mar 31
- Form 6-K NOVARTIS AG For: Mar 18
- Form FWP NOVARTIS AG Filed by: NOVARTIS AG
- Form 144 NOVARTIS AG Filed by: Marshall Fiona
- Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor
- Form S-8 NOVARTIS AG
- Form 6-K NOVARTIS AG For: Dec 31
- Form 6-K NOVARTIS AG For: Dec 31
- Form IRANNOTICE NOVARTIS AG
- Form 20-F NOVARTIS AG For: Dec 31
- Form S-8 POS NOVARTIS AG
- Form S-8 POS NOVARTIS AG
- Form S-8 POS NOVARTIS AG
- Form S-8 POS NOVARTIS AG
- Form 6-K NOVARTIS AG For: Nov 24
- Form 6-K NOVARTIS AG For: Nov 20
- Form 6-K NOVARTIS AG For: Nov 05
- Form FWP NOVARTIS AG Filed by: NOVARTIS AG
- Form 6-K NOVARTIS AG For: Sep 30
- Form 6-K NOVARTIS AG For: Oct 27
- Form 6-K NOVARTIS AG For: Sep 30
- Form 6-K NOVARTIS AG For: Aug 11
- Form 6-K NOVARTIS AG For: Jul 17
- Form SCHEDULE 13G NOVARTIS AG Filed by: UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
- Form 6-K NOVARTIS AG For: Jun 30
